Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status

Pharmacogenetics and Genomics

Volumn 15, Issue 12, 2005, Pages 851-859

  Ieiri, Ichiro ^a   Kimura, Miyuki ^b   Irie, Shin ^b   Urae, Akinori ^b   Otsubo, Kenji ^a   Ishizaki, Takashi ^c  

^a TOTTORI UNIVERSITY   (Japan)

^b Kyushu Clinical Pharmacology Research Clinic   (Japan)

^c TEIKYO HEISEI UNIVERSITY   (Japan)

Author keywords

CYP2C19; Pharmacodynamics; Pharmacogenetics; Pharmacokinetics; Ticlopidine

Indexed keywords

ADENOSINE DIPHOSPHATE; CYTOCHROME P450 2C19; OMEPRAZOLE; OMEPRAZOLE DERIVATIVE; TICLOPIDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DISPOSITION; DRUG METABOLISM; GENETIC DIFFERENCE; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; KINETICS; NORMAL HUMAN; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

EID: 27944496080     PISSN: 17446872     EISSN: None     Source Type: Journal    
DOI: 10.1097/01213011-200512000-00003     Document Type: Article

References (39)

1. Jacobson AK. Platelet ADP receptor antagonists: ticlopidine and clopidogrel. Best Pract Res Clin Haematol 2004; 17:55-64.
2. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 8649:1215-1220.
3. Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989; 321:501-507.
4. Balsano F, Rizzon P, Violi F, Scrutinio D, Cimminiello C, Aguglia F, et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. Circulation 1990; 82:17-26.
5. Scrutinio D, Cimminiello C, Marubini E, Pitzalis MV, Di Biase M, Rizzon P. Ticlopidine versus aspirin after myocardial infarction (STAMI) trial. J Am Coll Cardiol 2001; 37:1259-1265.
6. Bergqvist D, Almgren B, Dickinson JP. Reduction of requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: results from the Swedish Ticlopidine Multicentre Study (STIMS). Eur J Vasc Endovasc Surg 1995; 10:69-76.
7. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334:1084-1089.
8. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339:1665-1671.
9. Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 1998; 98:1597-1603.
10. Desager JP. Clinical pharmacokinetics of ticlopidine. Clin Pharmacokinet 1994; 26:347-355.
11. Knudsen JB, Bastain W, Sefton CM, Allen JG, Dickinson JP. Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics. Xenobiotica. 1992; 22:579-589.
12. Turpeinen M, Nieminen R, Juntunen T, Taavitsainen P, Raunio H, Pelkonen O. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. Drug Metab Dispos 2004; 32:626-631.
13. Richter T, Murdter TE, Heinkele G, Pleiss J, Tatzel S, Schwab M, et al. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther 2004; 308:189-197.
14. Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, Pelkonen O, Laine K. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther 2005; 77:553-559.
15. Ko JW, Desta Z, Soukhova NV, Tracy T, Flockhart DA. In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. Br J Clin Pharmacol 2000; 49:343-351.
16. Ha-Duong NT, Dijols S, Macherey AC, Goldstein JA, Dansette PM, Mansuy D. Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry 2001; 40:12112-12122.
17. Lopez-Garcia MP, Dansette PM, Mansuy D. Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid. Biochemistry 1994; 33:166-175.
18. Tateishi T, Kumai T, Watanabe M, Nakura H, Tanaka M, Kobayashi S. Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism. Br J Clin Pharmacol 1999; 47:454-457.
19. Dalvie DK, O'Connell TN. Characterization of novel dihydrothienopyridinium and thienopyridinium metabolites of ticlopidine in vitro: role of peroxidases, cytochromes p450, and monoamine oxidases. Drug Metab Dispos 2004; 32:49-57.
20. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194:927-929.
21. Donahue SR, Flockhart DA, Abernethy DR, Ko JW. Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19. Clin Pharmacol Ther 1997; 62:572-577.
22. Yu KS, Yim DS, Cho JY, Park SS, Park JY, Lee KH, et al. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther 2001; 69:266-273.
23. Jeppesen U, Rasmussen BB, Brosen K. Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. Clin Pharmacol Ther 1997; 62:279-286.
24. Kimura M, Ieiri I, Wada Y, Mamiya K, Urae A, Iimori E, et al. Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy. Br J Clin Pharmacol 1999; 47:115-119.
25. Ieiri I, Yamada S, Seto K, Morita T, Kaneda T, Mamiya K, et al. A CYP2D6 phenotype-genotype mismatch in Japanese psychiatric patients. Pharmacopsychiatry 2003; 36:192-196.
26. Picard-Fraire C. Pharmacokinetic and metabolic characteristics of ticlopidine in relation to its inhibitory properties on platelet function. In: Gordon JL (editors): Agents and Action Supplements, Vol. 15. Basel: Birkhauser Verlag; 1984, pp. 68-75.
27. Grieco A, Vecchio FM, Greco AV, Gasbarrini G. Cholestatic hepatitis due to ticlopidine: clinical and histological recovery after drug withdrawal. Case report and review of the literature. Eur J Gastroenterol Hepatol 1998; 10:713-715.
28. Martinez Perez-Balsa A, De Arce A, Castiella A, Lopez P, Ruibal M, Ruiz Martinez J, et al. Hepatotoxicity due to ticlopidine. Ann Pharmacother 1998; 32:1250-1251.
29. Zeolla MM, Carson JJ. Successful use of clopidogrel for cerebrovascular accident in a patient with suspected ticlopidine-induced hepatotoxicity. Ann Pharmacother 1999; 33:939-941.
30. Homberg JC, Andre C, Abuaf N. A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis. Clin Exp Immunol 1984; 55:561-570.
31. Lecoeur S, Bonierbale E, Challine D, Gautier JC, Valadon P, Dansette PM, et al. Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: comparison with two directly hepatotoxic drugs. Chem Res Toxicol 1994; 7:434-442.
32. Lecoeur S, Andre C, Beaune PH. Tienilic acid-induced autoimmune hepatitis: anti-liver and -kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9. Mol Pharmacol 1996; 50:326-333.
33. Beaune P, Dansette PM, Mansuy D, Kiffel L, Finck M, Amar C, Leroux JP, et al. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci U S A 1987; 84:551-555.
34. Obermayer-Straub P, Manns MP. Cytochrome P450 enzymes and UDP-glucuronosyltransferases as hepatocellular autoantigens. Mol Biol Rep 1996; 23:235-242.
35. Ellis DJ, Roe RL, Bruno JJ, Cranston BJ, McSpadden MM. The effects of ticlopidine hydrochloride on bleeding time and platelet function in man. Thromb Haemost 1981; 46:176.
36. Panak E, Maffrand JP, Picard-Fraire C, Vallee E, Blanchard J, Roncucci R. Ticlopidine: a promise for the prevention and treatment of thrombosis and its complications. Haemostasis 1983; 13(Suppl 1):1-54.
37. Ruan C, Destelle G, Wang Z, Wan H, He Y, Cheng D, et al. Ticlopidine in China: comparative study on the effect of two dose levels on bleeding time and platelet function in healthy volunteers. Haemostasis 1989; 19:94-99.
38. Di Minno G, Cerbone AM, Mattioli PL, Turco S, Iovine C, Mancini M. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. J Clin Invest 1985; 75:328-338.
39. Yoneda K, Iwamura R, Kishi H, Mizukami Y, Mogami K, Kobayashi S. Identification of the active metabolite of ticlopidine from rat in vitro metabolites. Br J Pharmacol 2004; 142:551-557.